Fresh analysis indicates that individuals who stop using new slimming jabs like Wegovy and Mounjaro tend to recover reduced body mass much more quickly than those who end conventional lifestyle programs.
Findings released in a prominent medical journal points out that while obese individuals often shed a large proportion of their body weight while on the medication, the mass comes back at an estimated rate of nearly a kilo each month after stopping.
"People purchasing such treatments must be cognizant of the potential of fast rebound weight gain when the therapy is stopped," stated researcher Dr. Susan Jebb.
This pace of recovery suggests a reversion to starting mass within about a year and a half.
Comparing Therapies
The analysis, which examined 37 of studies involving thousands of patients, contrasted the results of GLP-1 agonists with conventional dieting.
Researchers note that people who lose weight through diet and exercise usually see a less rapid weight regain—perhaps 100 grams monthly—once they finish.
Understanding the Quick Regain
Experts believe the mode of action of the jabs is key to understanding the heightened weight return.
The injections copy a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of GLP-1 levels several times higher than normal might result in the body to produce less of its own natural hormone, and may also lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication results in appetite is unsuppressed, making overeating much more probable."
A Lifelong Condition?
The NHS suggest the injections for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
Many experts say that, due to the significant potential of weight regain, the therapy should be considered long-term.
This view is echoed by drug manufacturers, who note that the results "underscore the chronic nature of excess weight," similar to managing conditions like diabetes.
User Testimonies
Users who have discontinued the medication describe a intense resurgence of cravings.
"It was like something that goes on and I was suddenly ravenous," recalled an individual.
This difficulty is worsened if patients have not developed permanent dietary or behavioural modifications during therapy.
Widespread Adoption
Recent estimates indicate that millions of people in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Adoption is greater among females compared to males.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
Ultimately, experts caution that while these medications are powerful agents for weight loss, they are not a standalone cure and long-term success likely depends on combined behavioural management.
